RESUMEN
Objective To explore the manufacturing process and performance of laser-cut 316L medical catheters based on catheter designs with different cutting methods.Methods Two design schemes of straight and oblique spiral cut were proposed under interrupted spiral cut pattern.Straight and oblique spiral cut medical catheters were obtained with desired laser parameters,cutting speed and focus position of the laser cutting machine,oxygen as the auxiliary gas and nitric acid and hydrofluoric acid as the acid cleaning solution for the post-treatment process,which were compared with Direxion torqueable microcatheter and tested for traceability,torsion control and tensile strength.Results Laser-cut 316L medical catheters were less likely to hurt blood vessels for its advantages over Direxion torqueable microcatheter in surface brightness and roundness of grooved edges,while Direxion torqueable microcatheter behaved better in intensity and width uniformity of grooves and regularity of semi circles at ends of grooves.Straight spiral cut medical catheters had the traceability,torsion control and tensile strength increased by 50％,22％and 33％respectively when compared with oblique spiral cut catheters.Conclusion Laser cutting parameters and post-treatment process are the main factors affecting the appearance and size of laser cut medical catheters,and also of importance for improving the qualified rate of product processing and assembly.The catheter cutting design scheme is also a key element influencing the physical properties of medical catheters.[Chinese Medical Equipment Journal,2024,45(1):31-36]
RESUMEN
<p><b>BACKGROUND</b>Three randomised trials have demonstrated that combining bevacizumab with first-line chemotherapy significantly improves progression-free survival versus chemotherapy alone in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). However, data from Chinese populations are limited and possible differences between ethnic and geographic populations are unknown. This study was conducted to determine whether there are differences in safety and efficacy in patients with HER2-negative LR/mRC between Chinese and Western populations after they receive first-line bevacizumab combined with taxane-based therapy.</p><p><b>METHODS</b>In the single-arm, open-label, Avastin Therapy for Advanced Breast Cancer (ATHENA) study (NCT00448591), patients with HER2-negative LR/mBC received first-line bevacizumab (investigator's choice of 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks) combined with taxane-based therapy. The primary endpoint was safety profile and the secondary is time to progression (TTP). A subpopulation analysis was conducted to assess safety and efficacy in Chinese patients.</p><p><b>RESULTS</b>Of 2264 patients treated in ATHENA, 202 were enrolled in China. Bevacizumab was combined with docetaxel in 90% of Chinese patients and paclitaxel in 10%. The most common grade 3/4 adverse events were diarrhoea (in 5.0% of patients) and hypertension (in 2.5% of patients). Grade 3/4 proteinuria occurred in 0.5%. After median follow-up of 17.6 months and events in 56% of patients, median TTP was 9.0 months (95%CI, 8.4-11.1). Overall survival data were immature.</p><p><b>CONCLUSIONS</b>We found no evidence of increased bevacizumab-related toxicity or reduced efficacy in Chinese LR/mBC patients receiving first-line bevacizumab-taxane therapy compared with predominantly Western populations. The safety profile was generally similar to previously reported LR/mBC trials. Subtle differences may be attributable to different lifestyle and cardiovascular risk factors in Chinese patients compared with the overall population. It appears reasonable to extrapolate findings from bevacizumab-based randomised trials to Chinese populations.</p>